Fore Biotherapeutics · Regulatory · plixorafenib (PLX120-03 / FORTE)
2.5.1 Product Development Rationale — BRAF/MAPK-Altered CNS Tumours
Module: 2.5 Clinical Overview · Section 2.5.1
Prepared: 11 Aug 2026
Status: Working draft — not submission-ready
Classification: Internal — Confidential
About this format — CTD Module 2.5.1
This document is written to ICH M4E(R2), the Common Technical Document format used for marketing applications (NDA / BLA / MAA). Module 2.5 is the Clinical Overview — the sponsor's critical analysis and argument, not a data dump; the data themselves live in Module 2.7 and Module 5.
Section 2.5.1, Product Development Rationale, is the Clinical Overview's opening section. It is expected to do four things: (1) identify the disease and the intended population; (2) summarise current therapy and its limitations; (3) state the unmet medical need; and (4) give the scientific rationale linking the product's mechanism to that need. A reviewer reads 2.5.1 to understand why this program exists before assessing whether the data support it — so the section is deliberately argumentative, and every claim in it must be traceable.
Disease-background content of the kind held in the histology overviews belongs here. That is why these summaries were retrofitted to this skeleton rather than left as standalone references.
2.5.1 Product Development Rationale — this document
2.5.2 Overview of Biopharmaceutics
2.5.3 Clinical Pharmacology
2.5.4 Overview of Efficacy
2.5.5 Overview of Safety
2.5.6 Benefits & Risks Conclusions
→ detail: 2.7.3 Efficacy · 2.7.4 Safety
⚠ Decision support — not medical or regulatory advice. Working draft. Every figure is traced to a named source and its exact location; gaps and contested points are marked rather than smoothed. Medical + regulatory HITL review required before any external use. Contains no trial or patient-level data beyond published sources.
2.5.1.1Therapeutic context & target population
Plixorafenib is a paradox-breaking (type II) RAF inhibitor developed for tumours driven by MAPK-pathway activation through BRAF. The five CNS histologies in scope are united not by anatomy or morphology but by that single axis — and they differ from one another in ways that determine whether, and how, a RAF inhibitor can work.
The clinically decisive split across all five is BRAF fusion versus BRAF V600E:
- Fusion-driven tumours (KIAA1549::BRAF — pilocytic astrocytoma, DLGNT) signal as RAF dimers. Type I RAF inhibitors are ineffective against them and can cause paradoxical ERK activation. This is a mechanistic exclusion, not a potency gap.
- V600E-driven tumours (PXA, epithelioid GBM, a minority of PA and a ~1% subset of GBM) signal as monomers and are addressable by type I inhibitors — where an approved competitor already operates.
Why this framing matters for 2.5.1. The development rationale is not "these tumours have BRAF alterations." It is that the fusion population is mechanistically excluded from the approved type I agents, and the V600E population that recurs or progresses on them has no defined next line. Sections 2.5.1.3–2.5.1.5 develop that argument.
2.5.1.2Disease background by histology
Condensed to what 2.5.1 requires: definition and classification, epidemiology, natural history, and the molecular driver. Full histology overviews — description → subtypes → localization → imaging → epidemiology → genetics → grading → WHO criteria → diagnostic checklist — are held in the linked detail documents and are the evidence base for this section.
| Histology | WHO grade | Molecular driver | Epidemiology | Natural history |
|---|
Pilocytic astrocytoma
Circumscribed astrocytic glioma |
1 |
KIAA1549::BRAF fusion most common; V600E less frequent; CDKN2A deletion adverse |
Children & young adults; cerebellum most common; also optic pathway/hypothalamus, brainstem, hemispheres, cord |
10-yr OS >85–90% (pediatric LGG). V600E: 10-yr PFS 27% (95% CI 12.1–41.9) vs 60.2% (53.3–67.1) wild-type |
DLGNT
Glioneuronal, leptomeningeal |
Not formally graded
mostly low-grade |
1p deletion + MAPK activation; KIAA1549::BRAF 96%; IDH-wildtype |
Predominantly pediatric; median age 5 y (range 5 mo–46 y; n=36); M:F ≈1.7:1 pooled (n=145/43 series) |
High OS, low PFS: 5-yr OS 83.3%±8.8 vs 5-yr PFS 15.9%±8.0 (n=30, on therapy). MC-1 vs MC-2 5-yr OS 100% vs 43% |
PXA
Pleomorphic xanthoastrocytoma |
2 or 3 |
BRAF V600E characteristic + CDKN2A/B homozygous deletion ~87–95% |
Children & young adults; mean age ≈26 y (26±16, n=71); 98% supratentorial, temporal lobe; superficial/cystic |
Better than the grade-4 histologies. Anaplasia 33/74 (44.6%) overall; ~21% at primary diagnosis |
Glioblastoma
IDH-wildtype |
4 |
TERTp 74.7%, EGFR amp 57.5%, +7/−10 94.8%. BRAF V600E only ~1% (3/312) |
Incidence 3.23/100,000; 49.1% of malignant CNS tumours; median age 65 y; M:F ≈1.6:1 |
mOS ~15 mo standard therapy (12.6 mo real-world); 5-yr survival 5.5% |
Epithelioid GBM
Morphologic pattern — see note |
4 |
BRAF V600E ~50% (7/13). TERT 54.5%; MGMT meth 45.4%; EGFR amp 0/33 |
Median age 36 y (range 9–67) — ~29 y younger than conventional GBM; M:F ≈ equal; cerebral hemisphere, cortical invasion 78.8% |
Median OS 10 months (range 6–31); 1/3/5-yr survival 63.6% / 39.4% / 0% |
Classification caveat that must survive into any submission text. Epithelioid GBM is not a listed WHO 2021 entity — morphologic subtypes are not carried in the classification, and eGBM is not named in the classification summary at all. Integrated molecular analysis of 64 such tumours found they do not form a separate cluster, distributing instead across canonical PXA, IDH-wildtype GBM and paediatric RTK1 GBM. Two consequences: (1) eGBM must be described as a morphologic pattern with V600E enrichment, not a distinct entity; (2) eGBM and PXA overlap — a V600E-mutant superficial epithelioid tumour may be classified either way, so the two populations in this table are not fully disjoint. Any enrolment or subgroup definition resting on "eGBM" must specify how it is operationally distinguished from anaplastic PXA.
2.5.1.3Current therapeutic options & their limitations
2.5.1.3.1 Surgery
Surgery is the preferred initial treatment across the low-grade histologies where complete resection can be safely achieved, and extent of resection is an independent prognostic variable. Its limitations are the origin of the unmet need:
- Resectability is anatomically determined. Cerebellar PA is frequently curable; optic-pathway/hypothalamic PA frequently is not — and the diencephalic subgroup does correspondingly worse (5-yr PFS 22% with V600E vs 52% wild-type).
- DLGNT is leptomeningeal and diffuse by definition — complete resection is not an available strategy.
- Gross-total resection does not secure BRAF V600E tumours. PDQ: "Even in patients who underwent a gross-total resection, recurrence was noted in one-third, suggesting that BRAF V600E tumors have a more invasive phenotype."
2.5.1.3.2 Conventional systemic therapy
Carboplatin ± vincristine, single-agent vinblastine, and TPCV in paediatric LGG; temozolomide-based therapy in glioblastoma.
| Regimen / setting | Outcome | Limitation |
|---|
| COG A9952 — carboplatin + vincristine (non-NF1) | 5-yr EFS 39% ± 4% | P = 0.10 — superiority was not demonstrated. Neither arm reaches durable control in most patients; both carry cytotoxic burden in young children. |
| COG A9952 — TPCV (non-NF1) | 5-yr EFS 52% ± 5% |
| DLGNT — carboplatin-based / radiotherapy | 5-yr PFS 15.9% ± 8.0 on therapy | High OS with low PFS: patients survive but progress repeatedly. Cumulative treatment exposure over a paediatric lifetime. |
| Glioblastoma — standard therapy | mOS ~15 months; 5-yr 5.5% | No curative option. |
| Epithelioid GBM | Median OS 10 months; 5-yr 0% | Treated as conventional GBM; no established regimen for the V600E-enriched subset. |
2.5.1.3.3 Approved MAPK-directed therapy — and what it does not cover
| Agent | Approved population | Published activity | What it leaves uncovered |
|---|
Tovorafenib (OJEMDA)
type II / pan-RAF |
FDA accelerated approval 23 Apr 2024 — paediatric LGG with BRAF fusion/rearrangement or V600. EMA conditional MA 22 Apr 2026 (Ipsen); confirmatory FIREFLY-2 |
FIREFLY-1, approval figures: ORR 51%, mDOR 13.8 mo
A separate published cut reports ORR 67% / mDOR 16.6 mo (Kilburn, Nat Med 2024) |
Paediatric LGG only. The competitive benchmark and the accelerated-approval precedent. Moving front-line via FIREFLY-2/LOGGIC (NCT05566795). |
Dabrafenib + trametinib
type I RAF + MEK |
FDA paediatric LGG BRAF V600E, ≥1 y (16 Mar 2023) · FDA tissue-agnostic BRAF-V600E solid tumours (22 Jun 2022) · EMA Finlee/Spexotras (15 Nov 2023) incl. explicit paediatric HGG V600E |
Pivotal RCT vs carboplatin/vincristine: ORR 46.6% vs 10.8%. Adult glioma: ROAR. R/R paediatric HGG: ORR 56%, mDOR 22.2 mo |
V600E only — mechanistically inactive against BRAF-fusion tumours, the majority of PA and the near-totality of DLGNT. Its tissue-agnostic approval is the structural template for FORTE. |
Belvarafenib · PF-07799933
investigational, CNS |
Not approved. Belvarafenib Ph2 BRAF-altered brain tumours (NCT07688356); PF-07799933 ± binimetinib (NCT05355701) |
PF-07799933: in-brain responses reported in RAF-refractory patients |
The CNS-penetrant competitor set. PF-07799933 pursues the same paradox-breaker thesis — the principal watch-item. |
The central limitation, stated plainly. The approved V600E agent does not address fusion-driven disease, and the approved BRAF-altered agent is confined to paediatric low-grade glioma. Neither covers: DLGNT, PXA, epithelioid GBM, V600E glioblastoma, or adults. That is the gap this programme is built against.
Two qualifications that must travel with that claim. (1) Targeted therapy in DLGNT has been tried and does not hold: trametinib responses are real but all patients progressed within 2 years (Campanelli 2025), and MEK-inhibitor series more broadly show high on-therapy control with off-treatment rebound. The need is for a different mechanism, not more MEK inhibition. (2) PXA is not untouched — it is explicitly named in dabrafenib+trametinib trial eligibility (NCT02684058, NCT03919071) and BRAF/MEK inhibitors are positioned for BRAF-altered PXA by the EANO/EURACAN/SNO guideline (Rudà 2022). The accurate statement is "guideline-supported and trial-accessible, but not approved" — not "no options."
2.5.1.4Unmet medical need
| Histology | Driver & addressability | Best current option | Residual unmet need |
|---|
Pilocytic astrocytoma
fusion majority |
KIAA1549::BRAF fusion — not addressable by type I RAF inhibition |
Surgery; carbo/VCR or TPCV (5-yr EFS 39–52%); tovorafenib if R/R paediatric LGG |
Fusion-driven disease in unresectable sites, and V600E tumours recurring after gross-total resection (one-third). Adults are outside the paediatric LGG approvals entirely. |
| DLGNT |
KIAA1549::BRAF 96% — fusion-dominant; not addressable by type I |
No standard of care. Carboplatin-based chemo / radiotherapy |
The starkest need of the five. 5-yr PFS 15.9% against 5-yr OS 83.3% — patients live for years while progressing repeatedly. Surgery is not available (leptomeningeal). No approved agent. |
| PXA |
V600E characteristic — addressable in principle |
Surgery; no approved targeted agent in this histology |
No approval covers PXA. Anaplastic (grade 3) and recurrent disease after resection have no defined systemic standard. |
| Epithelioid GBM |
V600E ~50% — the highest V600E enrichment of the five |
Treated as conventional GBM |
Median OS 10 months, 5-yr survival 0%, in patients with a median age of 36. High V600E prevalence with no targeted standard. |
Glioblastoma
IDH-wildtype |
V600E ~1% — small but defined |
Standard chemoradiation; mOS ~15 mo |
A rare but molecularly selected population with no targeted option. Small absolute numbers; V600E concentrates in epithelioid morphology. |
Where the need concentrates. Two populations carry the argument. (1) Fusion-driven disease — PA and DLGNT — mechanistically excluded from approved type I agents, and in DLGNT's case with no approved agent at all and no surgical option. (2) V600E disease outside the paediatric-LGG label — PXA, epithelioid GBM, V600E glioblastoma, and adults. Both are defined by molecular selection rather than histology, which is the structure the FORTE master protocol is built to test.
2.5.1.5Scientific rationale for plixorafenib
- Mechanism matches the excluded population. As a paradox-breaking type II RAF inhibitor, plixorafenib is designed to act on RAF dimers — the signalling species in BRAF-fusion tumours — without the paradoxical ERK activation that makes type I inhibitors unsuitable there. The mechanism is the reason the fusion population is addressable at all, not a marginal improvement in potency.
- The molecular target is shared across all five histologies. Every histology in §2.5.1.2 is MAPK-driven through BRAF. This supports a molecularly-defined, histology-agnostic development structure — the design of the FORTE phase 2 master protocol (NCT05503797).
- Two regulatory precedents, not one. (a) Tovorafenib — same type II class — achieved accelerated approval (23 Apr 2024) in paediatric LGG on single-arm ORR 51% / mDOR 13.8 mo, establishing the endpoints the agency accepts for BRAF-altered CNS tumours. (b) Dabrafenib+trametinib's tissue-agnostic BRAF-V600E approval (22 Jun 2022) establishes that a molecularly-defined, histology-agnostic indication is grantable — the structural template FORTE is built on. Supporting framework: the RACE for Children Act, under which BRAF sits on FDA's paediatric molecular-target list.
- The programme already carries agency recognition. Plixorafenib holds Fast Track (Sep 2022, BRAF Class 1/2), Orphan Drug (Mar 2023, primary brain & CNS malignancies) and — most significantly — Breakthrough Therapy designation (1 Apr 2026) in adult BRAF-V600E high-grade glioma, reported as the first BTD for a targeted therapy in HGG.
- Published CNS-specific activity. SNO 2023 (CTNI-76): 6 of 10 evaluable V600+ primary CNS tumour patients responded (ORR 60%), HGG 67%, mPFS 34.1 months. SNO 2024 (TRLS-02): n=113 including 5 children, V600E ORR 67%, mDOR 13.9 months, no paediatric DLTs. Earlier phase 1/2a: V600 MAPKi-naïve PR 39%, mDOR 32 months.
- Differentiation is monotherapy CNS coverage. The pan-RAF competitor pack (exarafenib, naporafenib, belvarafenib, lifirafenib) is anchored in NRAS melanoma rather than CNS and mostly requires a MEK partner. Plixorafenib sits in a three-agent CNS-penetrant cohort with tovorafenib and PF-07799933; its differentiation is dimer-selective fusion + V600 coverage as monotherapy with in-brain exposure — the object of the CSF-ctDNA study (NCT06610682).
Two strategic inconsistencies this section surfaces — both need a deliberate decision, not a wording fix.
(1) The designation does not match the positioning. The Breakthrough Therapy designation is for
adult BRAF-V600E high-grade glioma. The programme is positioned paediatric, FORTE enrolls
≥8 years, and
no Rare-Pediatric-Disease designation and no EMA designation were found. A reviewer reading 2.5.1 will see a paediatric rationale supported by an adult designation.
(2) The ORR denominators are not consistent across our own readouts. 6/10 (SNO 2023), 9 evaluable (de la Fuente 2024 CNS abstract), n=113 (SNO 2024) — with two different "67%" figures among them.
Every quoted ORR must carry its population and denominator. See the
citation register §3.
Two handling rules on the plixorafenib CNS data — both mandatory.
(1) Use the published abstract only. The figures above are from the published TRLS-02 CNS abstract (de la Fuente 2024, Neuro-Oncology 26(Suppl 4); NCT02428712). The internal SNO-2026 reinterpretation is a separate, embargoed analysis and must not be used in this document or any external-facing text before its embargo lifts.
(2) State the denominator, not the bare percentage. Write "6 of 9 evaluable" rather than "67%". The 9 evaluable patients are a subset of the 22 primary CNS tumour patients, and response assessment used RECIST (with RANO applied to some CNS cases) — not RANO throughout. A bare 67% invites a reviewer challenge that the qualified form does not.
2.5.1.6Evidence provenance, gaps & open items
2.5.1 is an argument, and an argument is only as strong as its weakest citation. The following are known weaknesses in the current evidence base and must be closed before this section is submission-ready.
| Item | Status | Detail & action |
|---|
| GBM localization & imaging | Review-grade only | Rests entirely on a review source (StatPearls); no supplied reference covers either. Replace with primary references. |
| PA imaging | No source | The base literature summary contains no imaging content and none of its five references is an imaging source. Add one. |
| PA incidence & sex | Gap | Not established in the supplied references. Every other histology carries both. A registry source (CBTRUS) would supply it. |
| eGBM V600E frequency | Conflicting | Use ~50% (7/13). A single-institution series reporting 33/33 (100%) is an ascertainment outlier — do not quote it. |
| eGBM entity status | Contested | Not a WHO 2021 entity; merges with PXA / IDH-wt GBM / paediatric RTK1 GBM on methylation. Operational definition required for any subgroup claim. |
| DLGNT 1q gain prognosis | Unresolved | Two studies disagree — and they are not independent (shared senior authorship; up to ~12 of 30 patients may overlap). Do not present as two independent cohorts. |
| COG A9952 significance | Resolved | 39% vs 52% carries P = 0.10. Superiority not demonstrated — the P value must travel with the figures. |
| PDQ ref [27] | Traceable only via PDQ | The diencephalic 22% vs 52% figure. Underlying primary not yet identified. Identify before submission use. |
| CBTRUS vs WHO 2021 | Caveat required | CBTRUS 2014–2018 predates WHO 2021; its "glioblastoma" is the histologic entity and does not map cleanly onto the molecular definition. State this if both are cited together. |
| Plixorafenib CNS data | Embargo control | Published abstract only. Embargoed SNO-2026 reinterpretation must not enter this document. |
—Supporting histology overviews
The full disease-background evidence base for §2.5.1.2, each in the structure the source deck uses.
- Pilocytic astrocytoma — Summary & References. ind_summary_pilocytic_astrocytoma §1–9 + prognosis/treatment (§P). BRAF V600E prognostic data, transformation risk, A9952, approved competitor.
- GBM & eGBM — Histology Overview. ind_summary_gbm_egbm_histology_overview §A1–A9 (GBM), §B1–B9 (eGBM), §C the eGBM/PXA differential.
- DLGNT & PXA — Clinical-Development Summary, Citation-Gap Analysis & References. ind_summary_dlgnt_pxa_report Slide-by-slide claim verification against primary sources; the DLGNT and PXA evidence base.
- GBM & eGBM — Reference-Coverage Analysis. ind_summary_gbm_egbm_readiness Which sections the supplied reference list can and cannot support.
Method & limits. This section was assembled from the four supporting documents above; every figure carried into it was verified against a primary source in those documents, with its table or named section recorded there. Figures are reproduced here without re-deriving them. This is a working draft of 2.5.1 only — it is not a submission document, has not been through medical or regulatory review, and deliberately retains the open items in §2.5.1.6 rather than resolving them by assertion. Competitive statements describe published approvals and published trial results only. The plixorafenib figures are from the published TRLS-02 abstract; the embargoed SNO-2026 reinterpretation is excluded by design.